PMA device
Oncomine Dx Target Test
Life Technologies Corporation · Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP, Class III) · First FDA decision Jun 22, 2017, newest Nov 19, 2025Cancer detection and genomic testing
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
16
PMA pathway
Device trials
0
Naming "Oncomine Dx Target"
MAUDE reports
2
Brand "Oncomine Dx Target", since 2015
PubMed studies
70
Mentioning "Oncomine Dx Target"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Oncomine Dx Target Test
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 16 decisions filed under this name.
- Oncomine Dx Target TestPMA supplement
P160045-S050 · Decided Nov 19, 2025 · 211 days after receipt · Normal 180 Day Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- Oncomine Dx Target TestPMA supplement
P160045-S049 · Decided Aug 8, 2025 · 234 days after receipt · Normal 180 Day Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- Oncomine Dx Target TestPMA supplement
P160045-S046 · Decided Oct 17, 2024 · 232 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
3 more FDA decisions with a free account
Older decisions: P160045-S035, P160045-S034, P160045-S031, P160045-S029, P160045-S028, P160045-S027, P160045-S025, P160045-S019, P160045-S005, P160045
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40210Palmetto GBAUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40278WPS Insurance CorporationUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40226CGS Administrators, LLCUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40222Noridian Healthcare Solutions, LLCUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40278WPS Insurance CorporationUpdated Sep 15, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40222Noridian Healthcare Solutions, LLCUpdated Aug 22, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40226CGS Administrators, LLCUpdated Aug 21, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40210Palmetto GBAUpdated Aug 18, 2025
Clinical trials
Device studies on ClinicalTrials.gov that name "Oncomine Dx Target", any status and sponsor, newest update first.
No registered device study names "Oncomine Dx Target".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Oncomine Dx Target", and for the whole product code for context.
This brand
2 reports: 2 malfunction, 0 injury, 0 death
Whole product code PQP
14 reports: 11 malfunction, 2 injury, 0 death
Newest reports for this brand
3003335080-2023-00001 · Received Jan 13, 2023 · Event dated Dec 13, 2022
Device type: Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP)
Device problem as coded: False Negative Result
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- ONCOMINE DX TARGET TEST PRODUCTMalfunction
3003335080-2017-00001 · Received Dec 15, 2017 · Event dated Nov 21, 2017
Device type: Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP)
Device problem as coded: Off-Label Use; Unexpected Therapeutic Results
Patient problem as coded: No Patient Involvement
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1704-2020 · Started Mar 16, 2020
Reason given: Extended Expiration Date prior to clearance
Cause as FDA categorized it: Incorrect or no expiration date · Device type: Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP)
Z-1705-2020 · Started Mar 16, 2020
Reason given: Extended Expiration Date prior to clearance
Cause as FDA categorized it: Incorrect or no expiration date · Device type: Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP)
Z-1706-2020 · Started Mar 16, 2020
Reason given: Extended Expiration Date prior to clearance
Cause as FDA categorized it: Incorrect or no expiration date · Device type: Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP)
3 more recall records with a free account
Published research
The most relevant PubMed records for "Oncomine Dx Target"[tiab]. The summary above synthesizes these.
- Clinical utility of the Oncomine Dx Target Test multi-CDx system and the possibility of utilizing those original sequence data.
Saito A, Terai H, Kim TJ, et al. · Cancer Med · 2024Research Support, Non-U.S. Gov't
- Comparison of diagnostic performance between Oncomine Dx target test and AmoyDx panel for detecting actionable mutations in lung cancer.
Nagakubo Y, Hirotsu Y, Yoshino M, et al. · Sci Rep · 2024Comparative Study
- Possible False Results With cobas® EGFR Mutation Test v2 and Oncomine Dx Target Test for EGFR Mutation.
Kanaoka K, Tamiya A, Inagaki Y, et al. · Anticancer Res · 2023
- Cost-effectiveness Analysis of the Oncomineࡊ Dx Target Test MultiCDx System Using Next-generation Sequencing and Single-gene Test in Advanced and Recurrent Nonsquamous Non-small-cell Lung Cancer.
Kohara T, Ikeda S, Ishikawa KB · JMA J · 2024
- Comparison of the analytical performance of the Oncomine dx target test focusing on bronchoscopic biopsy forceps size in non-small cell lung cancer.
Sakaguchi T, Nishii Y, Iketani A, et al. · Thorac Cancer · 2022
- Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.
Hirotsu Y, Nakagomi T, Nagakubo Y, et al. · Sci Rep · 2024
- Clinical utility of comprehensive genomic profiling versus Oncomine Dx target test in pathological stage II-III non-small cell lung cancer.
Yano K, Kaseda K, Nakamura K, et al. · Sci Rep · 2025
- Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations.
Murakami S, Yokose T, Shinada K, et al. · Thorac Cancer · 2022Research Support, Non-U.S. Gov't
- Nucleic Acid Quality Assessment is Critical to the Success of the Oncomine Dx Target Test for Lung Cancer.
Nagakubo Y, Hirotsu Y, Amemiya K, et al. · Mol Diagn Ther · 2023Research Support, Non-U.S. Gov't
- Suitability of Bronchoscopic Biopsy Tissue Samples for Next-Generation Sequencing.
Murakami S, Yokose T, Nemoto D, et al. · Diagnostics (Basel) · 2021
- Clinical importance of the range of detectable variants between the Oncomine Dx target test and a conventional single-gene test for EGFR mutation.
Sakaguchi T, Iketani A, Esumi S, et al. · Sci Rep · 2023
- Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.
Murakami S, Shinada K, Otsutsumi Y, et al. · Cancer Med · 2024Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code PQP.
- FoundationOne CDxFoundation Medicine, Inc. · PMA 2026
- FoundationOne Liquid CDxFoundation Medicine, Inc. · PMA 2026
- Guardant360 CDxGuardant Health, Inc. · PMA 2026
- Oncomine Dx Express TestLife Technologies Corporation · PMA 2026
- xT CDxTempus AI, Inc. · PMA 2026
- TruSight Oncology ComprehensiveIllumina, Inc. · PMA 2026
- FoundationOne®Liquid CDxFoundation Medicine, Inc. · PMA 2026
- FoundationOneCDx (F1CDx)Foundation Medicine, Inc. · PMA 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.